Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year target prices for Intercept Pharmaceuticals' shares. Their ICPT share price targets range from $14.00 to $31.00. On average, they predict the company's share price to reach $19.86 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analysts' expectations of $79.57 million. Intercept Pharmaceuticals had a negative net margin of 19.39% and a negative trailing twelve-month return on equity of 77.48%. The company's revenue was up 16.6% on a year-over-year basis. During the same period last year, the firm earned ($0.68) EPS.

Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).